This WAC war is pointless. Synvisc1 , Gel 1, Euflexxa and Monovisc all held WAC reporting until they were required to do so. All products had very high ASP’s that slowly dropped as the numbers finally trickled in. The same will hold true for Durolane.
BV will make up the shortfall by replacing reps with associates and reducing commissions. I keep the job to keep healthcare benefits and make money by my side gig. Keep fighting so BV can worry about you and overlook those of us who have figured out a way to stay. YES, the company is s#&t. Yes the leadership doesn’t care about you. Yes this job is no longer device but injectable pharmaceutical a DME product on the coverage downswing. Maybe we need a new fresh fracture study that we can cancel 1.5 years in. Or even better, cancel a study and then refuse to pay the group doing the study so they publish a hatchet job on us.